Predict your next investment

INTERNET | Internet Software & Services / Conferencing & Communication
ermscorp.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$3.5M

About ERMS Corp.

ERMS Corporation is the provider of Advantage- a secure, enterprise-class mass emergency notification system, delivered using the Software-as-a-Service (SaaS) based model. Advantage is made up of 7 tightly-integrated modules (Messenger, Roll Call, Crisis Manager, Mapper, HotLine, myAdvantage, and Library. Advantage provides the industry's highest level of adaptability, most inclusive API, reliability and advanced functionality. It allows organizations to use the system the way that best suits them. Advantage is sold as a complete solution (the opposite of add-ons) that empowers business continuity, crisis communication, and disaster recovery professionals to, quickly and reliably, prepare, execute, and report on the notification portion of their continuity plans.

ERMS Corp. Headquarter Location

2916 S Sheridan Way #300

Oakville, Ontario, L6J 7J8,

Canada

905-829-8216

Latest ERMS Corp. News

Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma

Jan 3, 2020

Abstract Embryonal rhabdomyosarcomas (ERMS) account for 2–3% of cancers in pediatric and adolescent populations. They are rarer in adults. We and others have reported that ERMS arising in the uterine cervix may harbor mutations in the gene encoding the microRNA biogenesis enzyme, DICER1, but a large series of cases has not been published. In the uterus, distinguishing ERMS from adenosarcoma can be very challenging, even for expert pathologists, and DICER1 alterations have been identified in a variable subset of uterine adenosarcomas. We hypothesized that DICER1 genetic testing may be useful in distinguishing between ERMS and adenosarcoma. We conducted a central pathology review-based study of 64 tumors initially thought to be uterine ERMS or adenosarcoma; 19 neoplasms had a consensus diagnosis of ERMS, 27 of adenosarcoma and for 18, no consensus diagnosis was reached. The median age at diagnosis was 30 years (range 2.5–69) for ERMS, 57.5 years (range 27–82) for adenosarcoma, and 65.5 years (range 32–86) for no consensus cases. In our series, the DICER1 mutation prevalence differed between the three groups: DICER1 alterations were present in 18/19 (95%) ERMS, 7/27 (26%) adenosarcomas (p < 0.001), and 4/18 (22%) no consensus cases. A germline alteration was present in 6/12 ERMS patients tested versus 0/6 adenosarcoma patients. Thus, although DICER1 mutations are near ubiquitous in uterine ERMS and are significantly less common in uterine adenosarcoma, DICER1 testing is only of value in distinguishing between the two neoplasms when a DICER1 mutation is absent, as this is helpful in excluding ERMS. On review of the clinical and radiological features of the single DICER1 wild-type cervical ERMS, this was thought most likely to be of vaginal origin. Given the significant prevalence of DICER1 germline pathogenic variants in uterine ERMS, all patients with this diagnosis should be referred to a genetics service. Fig. 2: Overview of the 64 tumors studied with their respective DICER1 testing results and histopathological diagnosis. Fig. 3: Workflow leading to final DICER1 alteration tallies for the 64 uterine tumors studied. Fig. 4: Photomicrographs of uterine embryonal rhabdomyosarcomas. Fig. 5: Photomicrographs of uterine adenosarcomas. References 1. Fletcher C, Hogendoorn P, Merterns F, Bridge J (eds.). World Health Organisation classification of tumours of soft tissue and bone. International Agency for Research on Cancer Press: Lyon, France, 2013. 2. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83–103.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.